Argos Therapeutics Participating in Strategies for an HIV Cure 2016 Meeting
DURHAM, N.C., Nov. 14, 2016 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the ArcelisŪ technology platform, today announced that the company is presenting at the Strategies for an HIV Cure 2016 meeting being held November 14-16 at the Natcher Conference Center on the main campus of the National Institutes of Health (NIH) in Bethesda, Maryland.
Irina Tcherepanova, Ph.D., senior director of research and development for Argos, is presenting a poster titled, "Development of an Autologous HIV Outgrowth Process for the Manufacture of Targeted Immunotherapy for Latent Reservoir Clearance."
The meeting is sponsored by the Division of AIDS (DAIDS) at the National Institute of Allergy and Infectious Diseases (NIAID) and covers topics including basic and translational research, drug discovery and development, and clinical research.
###
About the Arcelis® Technology Platform Arcelis®
is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient's individual disease. It is designed to overcome immunosuppression by producing a specifically targeted, durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis ® process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient's own dendritic cells, which are optimized from cells collected by a leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient's plasma, and administered via intradermal injection as an individualized immunotherapy.
About Argos Therapeutics
Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis ® technology platform. Argos' most advanced product candidate, AGS-003 , is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of mRCC. In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for RCC and for the treatment of NSCLC. Argos is also developing a separate Arcelis ® -based product candidate, AGS-004 , for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated clinical trial aimed at HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
Source: Argos Therapeutics
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
|
